Tuesday, CSL Limited's (CMXHF) CSL Seqirus announced real-world evidence from the 2023/24 U.S. season for populations six months to 64 years, showing that cell-based influenza vaccines offer greater protection in preventing test-confirmed influenza compared to standard egg-based vaccines.
Moreover, the data estimate 19.8 percent relative vaccine effectiveness of cell-based quadrivalent influenza vaccines versus standard egg-based quadrivalent vaccines.
The improved protection results were consistently observed across pediatric and adult age subgroups as well as for at-risk populations.
The company expects the data to help healthcare providers to further reduce the burden of influenza on their patients.
Currently, CSL's stock is moving up 9.39 percent to $147.67 on the OTC Markets.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.